Father and Son 982x327px

Fuel Our Fight

ACKC is the only major
kidney cancer grassroots
lobbying organization
raising money that goes
predominantly to fund
kidney cancer research

Donate Today
Researcher A 982x327px

2016 ACKC
Campaign for
Research Funding

Annual campaign to get a
$15 million appropriation
for kidney cancer research

Sign Up Now
Holding Hand 982x327px

Patient Guides:
Taking Charge of
Kidney Cancer

ACKC’s online pamphlets
inform and empower patients
and their caregivers

View the Guides
Slide background

Stay Connected

Join ACKC’s online
community of survivors,
caregivers, family and
friends by liking us
on Facebook…we’re
13,049 members strong!

Join Us Online

ACKC Point of View

  • The Cost of Cancer Medication

    Why are cancer drug prices skyrocketing? What can be done to rein in costs when drug companies are a “corporate monopoly” with the highest profits of any industry? The patient power of grass-roots groups such as ACKC may hold the solution, says Hagop Kantarjian, M.D., a leader in the in the fight to lower drug costs. Full article coming soon…


  • DoD Award for Enhancing Immune Checkpoint Inhibitors

    October 19, 2015

      Hans Hammers from Johns Hopkins Cancer Center won an Idea Award from the Department of Defense for Fiscal Year 2014 for “Enhancing Immune Checkpoint Inhibitor[1] Therapy in Kidney Cancer”. This is a two-year grant in the amount of $486,000 awarded to Dr. Hammers and Johns Hopkins. DoD grants have normally gone to pure researchers, but Dr. Hammers, aside from doing research, is also an eminent clinical oncologist who has made a number of presentations… More →

  • Phase 1 Trial of Cabozantinib in Combination with Nivolumab or Nivolumab Plus Ipilimumab

    July 14, 2015

    Exelixis Announces Start of Phase 1 Trial of Cabozantinib in Combination with Nivolumab or Nivolumab Plus Ipilimumab in Patients with Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors SOUTH SAN FRANCISCO, Calif. — (BUSINESS WIRE) — Jul. 13, 2015 — Exelixis, Inc. (NASDAQ:EXEL) today announced the initiation of a phase 1 trial of cabozantinib in combination with nivolumab alone or in combination with nivolumab plus ipilimumab in patients with advanced/metastatic urothelial (bladder) and other genitourinary tumors…. More →

  • Recent Advances in Kidney Cancer Research and Treatment

    May 1, 2015

    Dr. W. Marston Linehan, Chief of Urologic Oncology at the National Cancer Institute (NCI) recently spoke to the advocacy group that gathered in Washington, DC, for ACKC’s annual Campaign for Research Funding. Dr. Linehan spoke to the group in layman’s terms regarding the recent advances in kidney cancer research (see video below). He described the strong sense of hope and excitement for major breakthroughs that may be coming as researchers are making significant progress regarding… More →

  • Nivolumab Approved for Another Cancer

    March 7, 2015

    On March 4, 2015, the FDA approved the Bristo-Myers Squibb (BMS) immunotherapy drug nivolumab (Opdivo) for use in non-small cell lung cancer (NSCLC) patients for whom other drugs have failed. The approval was based on interim results in a Phase III trial testing nivolumab, at 3 mg/kg, against docetaxel, a chemotherapy drug. Nivolumb was found to have extended overall survival (OS) by three months over docetaxel, giving patients on nivolumab a median OS of 9.2… More →

  • Exposome

    February 16, 2015

    A recent segment on NPR, segment, reported about a study, involving tens of thousands of participants over a 50-year period, by Dr. Barbara Cohn from UC Berkeley looking into the effect of environmental factors on the development of breast cancer in mothers and their children. Dr. Cohn plans to map out what’s called the “exposome” (see exposome), which is a map of the exposure of an individual over his or her lifetime to various environmental and… More →